Novartis buys Amblyotech to develop digital therapy for amblyopia
By Akshay Kedari  Date: 2020-04-21

Novartis buys Amblyotech to develop digital therapy for amblyopia

Novartis has recently made an announcement confirming that it has concluded its acquisition of Amblyotech, which is a software startup based in the U.S. Novartis will collaborate with McGill University and Ubisoft to be able to continue with the development of Amblyotech’s acquired digital tech for treating amblyopia, or “lazy eye”.

Apparently, there have been estimations regarding the amblyopia affecting about 3% of the world population. Some of these people can be appropriate candidates for the therapy when it gets approved. The condition generally results in poor vision and various other problems with the quality of life, if it is left untreated.

The condition is capable of impacting both adults and children beyond their vision that makes it difficult to both maintain and drive a sense of autonomy. There are various options for treatment currently, that include atropine and patching, which are mostly associated with a lower sense of compliance as well as a low rate of success. The adults have a limited set of approved therapies.

Reportedly, Amblyotech is aimed at improving compliance and it uses passive video and active gaming technology with 3D glasses, which trains the eyes for working together in order to view a complete image. The software employs a visual representation, which is called dichoptic display, wherein each eye is offered different images by using a proprietary algorithm.

The software of Amblyotech had shown big improvements in children as well as adults vision in the early clinical study as compared to the ones with standard care and treatment.

Global Business Franchise Head for Ophthalmology, Nikos Tripodis stated that the software of Amblyotech is an excellent example how the company can recreate medicines by using digital technology, as the firm offers a solution that is non-invasive and has the potential to be considerably faster than compared to the current care standards like patching for adults and children who have been impacted by lazy eye.

 

Source Credit- https://www.globenewswire.com/news-release/2020/04/20/2018335/0/en/Novartis-acquires-Amblyotech-pursuing-novel-digital-therapy-for-children-and-adult-patients-with-lazy-eye.html

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Innovaccer unveils AI-enabled patient relationship management solution
Innovaccer unveils AI-enabled patient relationship management solution
By Akshay Kedari

Innovaccer, Inc., a healthcare company, has recently launched an AI (artificial intelligence) enabled patient relationship management solution. The new solution will streamline communication between the care teams and patients. In addition, the solu...

Geely Tech to rollout a smart battery swapping network across Jinan
Geely Tech to rollout a smart battery swapping network across Jinan
By Akshay Kedari

Geely Technology Group, a Chinese automobile manufacturer, and the Municipal Government of Jinan, China, have reportedly signed an all-round strategic cooperation deal to jointly develop a network of smart battery swapping service stations across Jin...

CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal
CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal
By Akshay Kedari

Chinese biotechnology company, CStone Pharmaceuticals has recently announced that it has completed the Share Subscription Agreement with Pfizer Inc. for its newly issued shares worth US$200 million. The move furthers the biotech’s multifaceted ...

Researchers bag $6Mn grant to study the link between Parkinson’s & aging
Researchers bag $6Mn grant to study the link between Parkinson’s & aging
By Akshay Kedari

A three-year grant worth $6 million, funded by the Michael J. Fox Foundation, was recently awarded to a collaborative research team from Michigan’s Van Andel Institute (VAI) and the University of Minnesota Medical School. The grant was given th...

EY announces availability of OpsChain Network Procurement solution
EY announces availability of OpsChain Network Procurement solution
By Akshay Kedari

Ernst & Young (EY), a global professional services network, has recently announced the availability of a first-of-its-kind OpsChain Network Procurement solution. The solution has been built on the company’s OpsChain platform. It will enabl...